As PSMA is highly expressed in prostate cancer (PCa) and also upregulated in metastatic, hormone-refractory carcinomas, it is an excellent target for imaging and therapy in nuclear medicine. The gene discussed is FOLH1; the disease is posterior cortical atrophy.